Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Alkermes, Inc. (NasdaqNM:ALKS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 14Earnings Announcement
Location
64 Sidney Street
Cambridge, MA 02139
Phone: (617) 494-0171
Fax: (617) 494-9263
Email: financial@alkermes.com
Employees (last reported count): 415
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 34%
·Over the last 6 months:
 · 16 insider sells; 115.0K shares
  (0.5% of insider shares)
·Institutional: 84% (128% of float)
(366 institutions)
·Net Inst. Buying: 3.51M shares (+6.16%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Alkermes, Inc. develops products that are based on sophisticated drug delivery technologies. The Company has several areas of focus, including controlled, sustained-release of injectable drugs, lasting several days to several weeks, utilizing its ProLease and Medisorb technologies, and the development of pharmaceutical products based on its proprietary Advanced Inhalation Research (AIR) pulmonary technology. The Company's current focus is on the development of broadly applicable drug delivery technologies that include injectable sustained-release of proteins, peptides and small molecule pharmaceutical compounds, the pulmonary delivery of both small molecules and proteins and peptides and drug delivery to the brain across the blood-brain barrier.
More from Market Guide: Expanded Business Description

Financial Summary
ALKS develops products based on drug delivery technologies. The Co.'s areas of focus are: controlled, release of injectable drugs, delivery of drugs into the brain, oral delivery of drugs and pulmonary delivery of small proteins. For the three months ended 6/30/01, revenues fell 46% to $15.5 million. Net loss applicable to Common totalled $8.3 million vs. income of $7.9 million. Results reflect the absence of milestone revenues, and higher research expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2001 Compensation
PayExer

Michael Wall, 72
Chairman
--  --  
Richard Pops, 39
CEO
$857K$13.1M
Robert Breyer, 57
Pres, Director
579K7.7M
David Broecker, 40
COO
--  --  
Raymond Bartus, Ph.D., 54
Sr. VP of Preclinical R&D
--  --  
Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ALKSAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$18.75 
Recent Price$25.60 
52-Week High
on 5-Sep-2000
$49.25 
Beta0.81 
Daily Volume (3-month avg)559.0K
Daily Volume (10-day avg)468.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-47.4%
52-Week Change
relative to S&P500
-29.4%
Share-Related Items
Market Capitalization$1.63B
Shares Outstanding63.7M
Float41.8M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 15-May-2000
Per-Share Data
Book Value (mrq)$2.22 
Earnings (ttm)-$0.71 
Earnings (mrq)-$0.13 
Sales (ttm)$0.74 
Cash (mrq)$4.40 
Valuation Ratios
Price/Book (mrq)11.52 
Price/EarningsN/A 
Price/Sales (ttm)34.61 
Income Statements
Sales (ttm)$42.6M
EBITDA (ttm)-$52.6M
Income available to common (ttm)-$40.4M
Profitability
Profit Margin (ttm)-82.1%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsMar 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-8.64%
Return on Equity (ttm)-25.13%
Financial Strength
Current Ratio (mrq)9.38 
Debt/Equity (mrq)1.56 
Total Cash (mrq)$280.2M
Short Interest
As of 8-Aug-2001
Shares Short3.50M
Percent of Float8.4%
Shares Short
(Prior Month)
3.82M
Short Ratio7.23 
Daily Volume484.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.